Hepion Pharmaceuticals, Inc.   Report issue

For profit Phase 2
Founded: Edison NJ United States (2013)

Organization Overview

First Clinical Trial
2020
NCT04480710
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Hepion Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

crv431 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1